- Bioequivalence data analysis
-
Park G, Kim H, Bae KS
- KMID: 2512009
- Transl Clin Pharmacol.
- 2020 Dec;28(4):175-180.
- doi: 10.12793/tcp.2020.28.e20
SAS® is commonly used for bioequivalence (BE) data analysis. R is a free and open software for general purpose data analysis, and is less frequently used than SAS® for BE... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels
-
Yoon DY, Lee S, Ban MS, Jang IJ, Lee S
- KMID: 2512007
- Transl Clin Pharmacol.
- 2020 Dec;28(4):189-198.
- doi: 10.12793/tcp.2020.28.e18
There are several hurdles to overcome before implementing pharmacogenomics (PGx) in precision medicine. One of the hurdles is unawareness of PGx by clinicians due to insufficient pharmacogenomic information on drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicting human pharmacokinetics from preclinical data: volume of distribution
-
Yim DS, Choi S
- KMID: 2512010
- Transl Clin Pharmacol.
- 2020 Dec;28(4):169-174.
- doi: 10.12793/tcp.2020.28.e19
This tutorial introduces background and methods to predict the human volume of distribution (Vd ) of drugs using in vitro and animal pharmacokinetic (PK) parameters. The physiologically based PK (PBPK)... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers
-
Ban MS, Kim YK, Kim B, Jung J, Kim Yi, Oh J, Yu KS
- KMID: 2512008
- Transl Clin Pharmacol.
- 2020 Dec;28(4):181-188.
- doi: 10.12793/tcp.2020.28.e17
Tamsulosin, an alpha-1 adrenoreceptor antagonist, has been used as a primary option for medical treatment of benign prostate hyperplasia. An open-label, single-dose, randomized, three-treatment, three-period, three sequence crossover study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes
-
Lee S, Lee S, Jang IJ, Yu KS, Rhee Sj
- KMID: 2512006
- Transl Clin Pharmacol.
- 2020 Dec;28(4):199-207.
- doi: 10.12793/tcp.2020.28.e21
Sulfonylurea (SU) and dipeptidyl peptidase-4 (DPP-4) inhibitors are most common secondary agents that are added to metformin monotherapy. Real-world studies have become increasingly important in providing evidence of treatment effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
